Brain metastases: Why less radiation, more often, improves outcomes
Multi-fraction stereotactic radiotherapy reduces local failure and radiation necrosis in resectable brain metastases compared to single-fraction approaches.
Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Olaparib demonstrated activity in HR-deficient metastatic triple-negative breast cancer and platinum-sensitive relapsed ovarian cancer without germline BRCA1/2 mutations.
Breast cancer home injections: Convenient for patients, complex for insurers
Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.
Salivary gland cancer: Is HER2-low the new HER2-positive?
Why are we still treating cancer prevention as adjunctive care?
Lung cancer in never smokers: The 60x risk factor you might be missing
Multicancer tests: Can we screen without knowing the outcome?
Multicancer early detection: Can we screen for what we can't treat?
Chemo hair loss: Why some patients feel it more deeply
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
Annual surveillance for cholangiocarcinoma in primary sclerosing cholangitis patients should include noninvasive imaging and serum CA 19-9, according to expert recommendations.
Liver disease: Is coffee a daily dose of prevention?
Regular coffee consumption is associated with a reduced risk of liver disease, with a specific daily intake range appearing most beneficial. The protective effect extends across various liver conditions, including fibrosis and cirrhosis.
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
A 24-week anti-PD-1 antibody regimen reduced HBsAg and enhanced HBV-specific T cell responses in patients with chronic hepatitis B, offering a potential functional cure strategy.
Why primary sclerosing cholangitis remains a therapeutic graveyard
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Seladelpar and elafibranor: second-line options for PBC
ACLF: Why G-CSF works for some, but fails others
MASH: Why diabetes management now demands a liver-first approach?
Peripheral arterial disease: Why early detection still eludes us
Peripheral arterial disease often goes undiagnosed until advanced stages, leading to preventable complications. Early detection is critical for improving patient outcomes.
GLP-1s: Is eligibility missing half your high-risk patients?
A 313,000-person Danish and UK analysis finds people with a BMI of 25-26.9, currently ineligible for GLP-1 receptor agonists, have coronary heart disease risk matching those who do qualify, if they also carry elevated remnant cholesterol or inflammation.
Evolocumab: Is LDL-C reduction finally translating to lives saved?
Evolocumab, a PCSK9 inhibitor, has demonstrated a potential to reduce the risk of death in patients at high cardiovascular risk, offering a critical addition to lipid-lowering strategies.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Tactical athletes need more than a sports physical
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Endocarditis: Why fixed-dose ampicillin often misses the mark
Hypertension: Do shorter wall squats work as well for older women?
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
Eloralintide combined with tirzepatide cut body weight by up to 23.3% at 48 weeks in adults with obesity and type 2 diabetes, phase 2b data show.
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Type 1 diabetes incidence in Norwegian children rose 11% after rotavirus vaccination began, but similar rises followed unrelated vaccine changes.
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
The 2026 ADA and EASD consensus advocates early SGLT2 inhibitor or GLP-1-based therapy, potentially from diagnosis, and makes weight a formal treatment target.
CBL-514: Is visceral fat reduction the real story?
Bariatric surgery: The hidden hernia risk you're missing
Survodutide: Is 9.8% weight loss enough for its GI cost?
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
Type 1 diabetes screening: Why one protocol worked across 8 nations
Marathon running with type 1 diabetes: Is it finally safe?
Lifelong odor sensitivity: What early exposure means for your patients?
Early-life exposure to specific odors permanently suppresses an odor processing channel in Drosophila, demonstrating lifelong changes to odor sensitivity via glial pruning.
Spike sorting: Is your 'black box' holding back neural insights?
Understanding the intricate process of spike sorting is essential for interpreting neural recordings. A modular approach promises greater transparency and adaptability in this complex analytical task.
Epilepsy: Is art the missing piece in holistic patient care?
A new exhibit showcases artists living with epilepsy, aiming to reframe public perception of the condition beyond its clinical manifestations.
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
Fibromyalgia: Is the pain real if the tissue damage isn't?
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Can mice learn to control their own brains? A new neurofeedback system
Routine childhood vaccines: Less coverage means more than just infections
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full story
Idiopathic Pulmonary Fibrosis
Clostridioides difficile
• Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12LIVEUEG Week 2026 • Barcelona, ES • Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
AdvertisementAdvertisementAdvertisement
Advertisement
BarcelonaOct 17 – 20 2026Get on-site reporting the moment it publishes.
BarcelonaAttending UEG Week 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
